My watch list
my.chemeurope.com  
Login  

Mupirocin



Mupirocin
Systematic (IUPAC) name
9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[ [(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
Identifiers
CAS number 12650-69-0
ATC code D06AX09 R01AX06
PubChem 446596
Chemical data
Formula C26H44O9 
Mol. mass 500.622 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 97%
Metabolism  ?
Half life 20 to 40 minutes
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Mupirocin (pseudomonic acid A, or Bactroban or Centany) is an antibiotic originally isolated from Pseudomonas fluorescens. It is used topically, and is primarily effective against Gram-positive bacteria. Mupirocin is bacteriostatic at low concentrations and bactericidal at high concentrations.[1]

Additional recommended knowledge

Contents

Mechanism

It has a unique mechanism of action, which is selective binding to bacterial isoleucyl-tRNA synthetase, which halts the incorporation of isoleucine into bacterial proteins. Because this mechanism of action is not shared with any other antibiotic, mupirocin has few problems of antibiotic cross-resistance.

Uses

It is used as a topical treatment for bacterial skin infections, for example, furuncle, impetigo, open wounds etc. It is also useful in the treatment of methicillin-resistant Staphyolococcus aureus (MRSA), which is a significant cause of death in hospitalized patients who have received systemic antibiotic therapy. It is suggested, however, that mupirocin not be used for extended periods of time, or indiscriminately, as resistance does develop, and could, if it becomes widespread, destroy mupirocin's value as a treatment for MRSA. It may also result in overgrowth of non-susceptible organisms.

Sources

The original manufacturer's (GlaxoSmithKline) product is Bactroban. It is now available as a generic. One source is manufactured by Ortho-McNeil Pharmaceutical called Centany. Another is from Teva Pharmaceutical Industries which is simply called Mupirocin Ointment.[2]

References

  1. ^ Moodabe, Kate; Linda Bryant. "Topical antibiotics - more harm than good?", Focus, pp. 1. Retrieved on 2007-04-20. 
  2. ^ Teva Announces Approval Of Mupirocin Ointment
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Mupirocin". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE